Each person’s cancer journey is different. No two diagnoses unfold in the same way, and neither do two immune systems respond alike. Yet conventional cancer treatment models still lean on standardized protocols, often targeting the tumor while overlooking the individual behind it. Immunity Therapy Center (ITC) turns that equation around. Instead of forcing patients into a preset path, ITC builds treatment around the individual, combining advanced therapies with personalized care. The process begins with listening. Every patient receives a no-cost consultation where doctors study medical records, run detailed assessments and take time to understand concerns and goals. That foundation ensures the plan is designed for the person, never one-size-fits-all. Treatment then shifts from fighting disease to rebuilding resilience. Immune therapies, intravenous infusions, ozone, oxygen and enzyme treatments are woven together with nutrition, detoxification and lifestyle guidance. Biomagnetic therapy helps reset cellular signals, while targeted interventions address toxins, infections, microbiome imbalances, and nutritional deficiencies. “The aim is not only to shrink tumors,” says Dr. Carlos Bautista, founder. “It’s to restore balance, strengthen the immune system and make recovery an active part of treatment rather than something left until the end.” While traditional oncology often locks patients into rigid cycles that change only when new scans demand it, ITC doctors meet with patients daily, track progress in real time and adjust therapies immediately. This feedback loop brings quicker relief, keeps treatment aligned with the body’s responses and reassures patients that their journey is actively guided every step of the way. Support extends beyond medicine. Healing is reinforced by the environment inside the center—shared meals in the onsite restaurant, conversations in group treatment areas and friendships with fellow patients walking the same road. These connections transform treatment from an isolating experience into a shared journey of hope. Dr. Bautista’s daily presence strengthens this atmosphere. He personally meets patients, reviews outcomes and guides the medical team. Even before leaving, patients take part in exit interviews, ensuring their feedback directly shapes how care continues to evolve..

Driven by the purpose of bringing health and wellbeing to all, Grupo Dökka has emerged as one of Latin America’s leading forces in healthcare distribution. The company’s propulsion is a unique combination of pharmaceutical distribution, biomedical equipment distribution, retail pharmacies and digital health platforms. “We have built an integrated ecosystem that addresses the needs of patients, healthcare institutions and governments alike,” says Mr. Eduardo Jiliberto, CEO. “Our vision blends innovation with inclusivity, creating a foundation for more equitable and efficient healthcare access across the region.” Grupo Dökka’s pharmaceutical distribution proposition is built on logistics excellence, consulting, technology, and knowledge. Governments rely on the company as a trusted partner to ensure that low-income populations have timely access to medicine. Grupo Dökka partners with prestigious international brands in biomedical equipment and collaborates closely with doctors and institutions. Its specialized teams ensure that innovative technologies are introduced through models designed for both sustainability and accessibility. The retail side of the business reinforces its leadership position in Costa Rica. Two distinct pharmacy chains serve different needs: Farmacias La Bomba, which follows an “everyday low price” model, and Farmacia Fischel, which offers a high-end experience with wellness and dermocosmetic products. .

Founded in 2019 and headquartered in Guatemala City, BIOTI has positioned itself at the forefront of preventive cancer diagnostics and genetic testing in Latin America. Co-founded by Sebastián Yurrita, director of the genetic laboratory and expert in human genetics and genomics, the company has redefined how early detection and precision medicine are delivered across the region. By harnessing cutting-edge technologies and tailoring solutions to the unique challenges of Latin American healthcare systems, BIOTI has built a reputation for innovation, accessibility, and life-saving impact. To achieve this, BIOTI is leveraging advanced genetic testing and molecular diagnostics to detect cancer years before tumors develop. “By revealing cancer early and guiding the right treatment, we give patients peace of mind, better survival chances, and protection from the crushing costs of late-stage care,” says Yurrita. The results of early detection speak volumes. BIOTI’s advanced genetic techniques can even project risks decades into the future, enabling physicians to select the most effective drug therapies for each unique case. Another hallmark of the company’s work is the breadth of its diagnostic capabilities. BIOTI offers more than 800 different genetic tests that cover fields ranging from oncology and pediatrics to cardiology, neurology, endocrinology, rheumatology, gynecology, and nutrition. Rather than relying on years of trial-and-error diagnostics, it enables physicians to identify a patient’s condition with a single comprehensive test. This saves valuable time, reduces healthcare costs, and allows for rapid, accurate treatment. Importantly, BIOTI has also made affordability a core part of its mission, recognizing that equitable access to genetic testing is essential in a region where healthcare inequality remains a pressing challenge. BIOTI’s impact has been most profound in its relationships with physicians. Doctors, often confronted with complex cases that exceed the limits of traditional laboratory tests, have embraced genetic diagnostics as a powerful ally. Their trust has been instrumental in spreading BIOTI’s reach, as word of mouth among medical professionals has encouraged both private and public hospitals to adopt its services. The public sector, in particular, has emerged as a key partner, ensuring that even underserved populations can benefit from genetic testing..